Growing load of degenerative valve disease
In Benelux, the prevalence of valvular heart disease is rising steadily, particularly among the aging population. Conditions such as aortic stenosis and mitral regurgitation are being diagnosed more frequently due to the widespread use of advanced diagnostic tools such as echocardiography and cardiac MRI. Increasing awareness among general practitioners and cardiologists has led to earlier detection, driving the demand for innovative treatment options that are less invasive than traditional open-heart surgery.
Healthcare systems in Belgium, the Netherlands, and Luxembourg are well-established, with a focus on high-quality cardiac care. Hospitals are equipped with state-of-the-art catheterization labs and experienced interventional cardiologists, making transcatheter heart valve procedures a feasible option for patients who are at higher surgical risk. Moreover, public and private insurance coverage in the region supports access to these advanced therapies, encouraging clinicians to consider transcatheter interventions for suitable patients rather than relying solely on surgical approaches.
Patient awareness also plays a key role in driving demand. Many elderly individuals prefer minimally invasive treatments that allow faster recovery and reduced hospital stays. Coupled with ongoing clinical research and trials in the region, this trend is increasing confidence among physicians and patients in transcatheter heart valves. The combination of a growing patient population, strong healthcare infrastructure, and supportive reimbursement frameworks makes the prevalence of valvular heart disease a major driver of market growth in Benelux.
Growth of mitral & tricuspid transcatheter use
While the aortic valve remains the primary focus for transcatheter interventions, there is growing clinical interest in treating mitral and tricuspid valve disorders in Benelux. Improved imaging techniques and specialized training programs for cardiologists are enabling earlier diagnosis and better evaluation of these complex valve conditions. As a result, hospitals are gradually expanding their procedural offerings to include mitral and tricuspid transcatheter solutions, creating significant opportunities for device manufacturers and healthcare providers.
Patients with mitral and tricuspid valve dysfunction are often older or have other health complications that make traditional surgery riskier. Minimally invasive transcatheter procedures allow these patients to access treatment with lower risk and faster recovery. Cardiac centers in urban hubs such as Brussels, Amsterdam, and Luxembourg City are performing these interventions, often supported by multidisciplinary heart teams that ensure optimal patient selection and post-procedure care.
For medical device companies, this trend represents a clear growth opportunity. By collaborating with hospitals and offering training, education, and procedural support, manufacturers can help expand the use of transcatheter therapies for mitral and tricuspid valves. With increasing clinical confidence and patient acceptance, this segment is poised to become an important driver of transcatheter heart valve adoption across the Benelux region.
